Trial Profile
A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine±OMV, When Administered to Healthy Infants at 2, 4, 6 and/or 12 Months of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine group B OMV Novartis (Primary) ; Aluminium hydroxide; Hib-DTaP-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis Vaccines
- 04 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record (Parent trial: NCT00381615).
- 13 Jan 2010 New source identified and integrated (United Kingdom Clinical Research Network).
- 13 Oct 2006 New trial record.